Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06389513
PHASE4

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Sponsor: CanSino Biologics Inc.

View on ClinicalTrials.gov

Summary

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.

Official title: Phase IV Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Key Details

Gender

All

Age Range

3 Months - 3 Months

Study Type

INTERVENTIONAL

Enrollment

3011

Start Date

2024-06-12

Completion Date

2025-12

Last Updated

2025-08-15

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

MCV4

4 doses of vaccine on Day 0, Day30, Day 60 and Month 12

Locations (1)

Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention

Nanjing, China